drugset / Trial / NCT04130204

Topical Application to Relieve Gout: Efficacy Trial & Safety (TARGETS)

NCT04130204

Phase 2 Completed 284 enrolled Dyve Biosciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This overall goal of this trial will be to demonstrate that DYV700 is safe and effective as a treatment for acute gout flares.

Timeline

Start
2020-02-12
Primary completion
2021-05-21
Completion
2021-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject DYV700 Unknown 10 ml Topical
Background Colchicine Small molecule 0.6 mg

Indications